Novo Nordisk
Novo Nordisk presents positive long-term results for Saxenda
June 3, 2016Medical Communications, Research and Development Novo Nordisk, cardiometabolic risk factors, liraglutide, saxenda, weight loss
Novo Nordisk has presented analysis covering three years of a late-stage trial for Saxenda (liarglutide 3mg) , which showed the …
FDA committee unanimously recommends Novo Nordisk diabetes combo, IDegLira
May 25, 2016Research and Development, Sales and Marketing FDA, Novo Nordisk, Panel, Tresiba, Victoza, committee, ideglira, recommendation, staff
Novo Nordisk has announced that a US Food and Drug Administration (FDA) advisory committee has unanimously recommended IDegLira, a type-2 …
Novo Nordisk Q1 operating profit down 10% in local currencies
April 29, 2016Medical Communications, Sales and Marketing Financial, Novo Nordisk, Q1, earnings, outlook, results
Denmark’s Novo Nordisk (NYSE: NOV) on Friday posted a 10% drop in first-quarter operating profit and said it maintains its full year …
Novo unveils new research grant to mark World Haemophilia Day
April 18, 2016Medical Communications, Research and Development, Sales and Marketing Novo Nordisk, grant, haemophilia, hero, world haemophilia day
Novo Nordisk has marked World Haemophilia Day 2016 with the announcement of a new research grant aimed at supporting and …
Novo says Victoza bests MSD’s Januvia at lowering blood sugar
April 4, 2016Research and Development Novo Nordisk, Victoza
Novo Nordisk says its diabetes drug Victoza, in combination with metformin, outperformed MSD’s Januvia plus metformin in reducing HbA1c – …
Novo Nordisk breaks ground on new $2 billion production facility in North Carolina
March 29, 2016Manufacturing and Production, Research and Development $2 billion, Clayton, Novo, Novo Nordisk, building, diabetes, nordisk, north carolina, production facility
Novo Nordisk has begun work on a new $2 billion production facility in Clayton, North Carolina, which will produce active …
Novo Nordisk reports five-year Victoza cardiovascular safety data
March 7, 2016Research and Development, Sales and Marketing Novo Nordisk, Victoza
Novo Nordisk has announced the top-line results from a trial investigating the cardiovascular safety of Victoza (liraglutide [rDNA origin] injection) …
Novo says diabetes drug Xultophy cost-effective versus insulin intensification treatment
March 2, 2016Sales and Marketing Novo Nordisk, Xultophy, diabetes
Novo Nordisk says findings show its Tresiba and Victoza combo Xultophy (insulin degludec/liraglutide: IDegLira), is cost-effective compared to insulin intensification …
Novo Nordisk says Tresiba reduces hypoglycaemia risk vs Lantus
February 23, 2016Manufacturing and Production, Research and Development Novo Nordisk
Novo Nordisk has announced trial results suggesting that its drug Tresiba (insulin degludec) carries a reduced risk of hypoglycaemia episodes, …
Novo Nordisk files for new insulin approval
December 10, 2015Manufacturing and Production, Research and Development, Sales and Marketing FDA, NDA, Novo Nordisk, NovoLog, diabetes, insulin aspart, new drug application
Novo Nordisk has submitted a New Drug Application (NDA) for faster-acting insulin aspart to the FDA. If successful, the Danish …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
Novo Nordisk buys Xoma diabetes program and scores trial successes
December 2, 2015Research and Development, Sales and Marketing Novo Nordisk, Ryzodeg, SGLT2 inhibitors, Victoza, Xoma, diabetes
Novo Nordisk has announced its purchase of a type 2 diabetes diabetes program in a deal with biotech firm Xoma …
Novo Nordisk looks to HEOR data to back Victoza
November 11, 2015Research and Development, Sales and Marketing Byetta, HEOR, Lyxumia, NHS, Novo Nordisk, Victoza, cost-effectiveness
A Novo Nordisk-sponsored study of the cost-effectiveness of three different injectable anti-diabetes drugs has found Victoza is a cheaper option …
Jardiance scores more cardiovascular outcomes data
November 10, 2015Manufacturing and Production Boehringer, Boehringer Ingelheim, Eli Lilly, Novo Nordisk, Victoza, cardiovascular outcomes, diabetes, empagliflozin, jardiance, lilly, liraglutide, type 2 diabetes
A sub-group analysis of data from an outcomes study of Boehringer Ingelheim’s and Lilly’s Jardiance has found the diabetes drug …
Novo Nordisk invests in new insulin-filling facility
November 4, 2015Manufacturing and Production Denmark, Novo Nordisk, manufacturing, production
Novo Nordisk is investing 2.1 billion Danish Kroner (about £200m) in a new facility in Hillerød, Denmark, which will produce diabetes …
Latest content
Global coalition calls for stronger government action on COPD
Global health researchers call for more equitable partnerships
Liverpool launches £20m lab for infectious disease drug discovery
Circle Health Group expands into UK laboratory operations
FibroFind appoints Professor Andrew Fisher as Chief Medical Officer
